Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9MA8O)

• Drug Name: Molsidomine Drug Info
• Synonyms: molsidomine; morsydomine; Corvaton; 25717-80-0; Molsidolat; Motazomin; SIN-10; Sydnopharm; Morial; N-Ethoxycarbonyl-3-morpholinosydnonimine; Molsidominum [INN-Latin]; Molsidomina [INN-Spanish]; Molsidomin; MLS000028573; UNII-D46583G77X; CAS 276; EINECS 247-207-4; BRN 3999414; SMR000058990; Sydnone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)-; N-Carboxy-3-morpholinosydnonimine ethyl ester; N-Carboxy-3-morpholinosydnone imine ethyl ester; N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine; Corvasal; Coruno; Sydnone imine, N-carboxy-3-m

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]

• Cross-matching ID:
  PubChem CID: 5353788
  ChEBI ID: CHEBI:92623
  CAS Number: CAS 25717-80-0
  TTD Drug ID: DM9MA8O
  INTEDE Drug ID: DR1105

Molecule-Related Drug Atlas

Drug(s) Affected By Frataxin, mitochondrial (FXN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[4]
Betamethasone	DMAHJEF	Acute adrenal insufficiency		Approved	[3]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[5]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[7]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[8]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[9]
Deferiprone	DMS2M7O	Beta thalassemia	3A50.2	Approved	[3]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[10]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Phosphodiesterase 5A (PDE5A) Main DME	DE37ABY	PDE5A_HUMAN	Substrate	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Gene/Protein Processing	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (id: DB09282)
• [3] Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
• [4] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [5] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [6] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [7] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [8] Oxidative stress-dependent frataxin inhibition mediated alcoholic hepatocytotoxicity through ferroptosis. Toxicology. 2020 Dec 1;445:152584. doi: 10.1016/j.tox.2020.152584. Epub 2020 Oct 2.
• [9] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [10] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [11] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.